Drug EfficacyPaltusotine’s 56% response rate on IGF-1 normalization is a significant improvement over the typical rates for existing treatments, indicating strong efficacy.
Market PotentialWith an anticipated broad label for treatment and the potential to dominate the acromegaly market, paltusotine is poised to significantly increase patient adoption and sales.
Safety And ConvenienceThe safety and tolerability profile of paltusotine, combined with the convenience of an oral formulation, offers a compelling alternative to injectable options.